0001209191-21-026076.txt : 20210408
0001209191-21-026076.hdr.sgml : 20210408
20210408163511
ACCESSION NUMBER: 0001209191-21-026076
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210406
FILED AS OF DATE: 20210408
DATE AS OF CHANGE: 20210408
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Knowles Julius
CENTRAL INDEX KEY: 0001808365
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39264
FILM NUMBER: 21815266
MAIL ADDRESS:
STREET 1: C/O KEROS THERAPEUTICS, INC.
STREET 2: 99 HAYDEN AVENUE, SUITE 120, BUILDING E
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Keros Therapeutics, Inc.
CENTRAL INDEX KEY: 0001664710
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E)
STREET 2: LEDGEMONT TECHNOLOGY CENTER
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-513-8774
MAIL ADDRESS:
STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E)
STREET 2: LEDGEMONT TECHNOLOGY CENTER
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-04-06
0
0001664710
Keros Therapeutics, Inc.
KROS
0001808365
Knowles Julius
C/O KEROS THERAPEUTICS, INC.
99 HAYDEN AVENUE, SUITE 120, BUILDING E
LEXINGTON
MA
02421
1
0
0
0
Common Stock
2021-04-06
4
S
0
1889
58.22
D
604885
I
See footnote
Common Stock
2021-04-06
4
S
0
1233
58.22
D
404452
I
See footnote
Common Stock
2021-04-06
4
S
0
3685
59.10
D
601200
I
See footnote
Common Stock
2021-04-06
4
S
0
2402
59.10
D
402050
I
See footnote
Common Stock
2021-04-06
4
S
0
54
59.95
D
601146
I
See footnote
Common Stock
2021-04-06
4
S
0
35
59.95
D
402015
I
See footnote
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.74 to $58.735 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5) and (6).
The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.
The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.74 to $59.70 inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.94 to $60.00 inclusive.
/s/ Keith Regnante, Attorney-in-Fact
2021-04-08